JAMSS supports COVID-19 space research consortium
A consortium has been initiated by Innostudio Inc. (HU) for the development and validation of highly efficient active compounds against SARS-CoV-2 while conducting drug discovery simultaneously and in a synchronized manner in space and on Earth.
The outcome of the project are expected to be a promising solution not only for understanding how to efficiently treat COVID-19 but also for supporting the rapid control of virus outbreaks of the future.
JAMSS will contribute as the consortium member with Kirara that is commercial service for the high quality protein crystallization in International Space Station (ISS).
Kirara is a high quality protein crystal growth service provided by JAMSS for drug discovery support. This technology was realized through a technical tie-up with Confocal Science, which has been supporting protein crystal generation on ground and in space since its foundation in 1994. The small incubator, which JAMSS developed and in which crystals are grown, is launched through the ICE Cubes Service and accommodated in the ICE Cubes Facility (ICF) owned by Space Applications Services who has a commercial partnership with the European Space Agency (ESA). Kirara is a commercial service partnership between Japanese and European companies. It could be applied to the field of materials such as cellulose as well as drug discovery support. Refer to the following website for details.
June-12th, 2020 InnoStudio Launches a Consortium for Developing Coronavirus Drugs Based on Simultaneous Research in Space and Earth Environments